Association of preoperative antiviral treatment with incidences of post-hepatectomy liver failure in hepatitis B virus-related hepatocellular carcinoma

Figure 1 Flow chart of the patient enrolling process. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen.

Figure 2 The receiver operating characteristic curve of hepatitis B virus DNA value for predicting the occurrence of post-hepatectomy liver failure.

Figure 3 Comparison of the receiver operating characteristic curves for predicting post-hepatectomy liver failure using each reference score model alone and the new model combining hepatitis B virus DNA level. A: The receiver operating characteristic (ROC) curves of albumin-bilirubin (ALBI) and ALBI + hepatitis B virus (HBV) DNA level; B: The ROC curves of fibrosis-4 (FIB-4) and FIB-4 + HBV DNA level; C: The ROC curves of aspartate aminotransferase-to-platelet ratio index (APRI) and APRI + HBV DNA level. ROC: Receiver operating characteristic; ALBI: Albumin-bilirubin; AUROC: The area under the receiver operating characteristic; HBV: Hepatitis B virus; FIB-4: Fibrosis-4.

Figure 4 Decision curve of the reference score models and the developed models combining hepatitis B virus DNA level. A: Decision curves of albumin-bilirubin (ALBI) and ALBI + hepatitis B virus (HBV) DNA level; B: Decision curves of fibrosis-4 (FIB4) and FIB4 + HBV DNA level; C: Decision curves of aspartate aminotransferase-to-platelet ratio index (APRI) and APRI + HBV DNA level. ALBI: Albumin-bilirubin; HBV: Hepatitis B virus; FIB-4: Fibrosis-4.